---
title: "Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295260899.md"
description: "Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market."
datetime: "2026-08-07T16:54:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295260899.md)
  - [en](https://longbridge.com/en/news/295260899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295260899.md)
generator: "portal-rs"
---

# Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [REPL: TUDRIQEV launch targets rapid adoption in key accounts, with expansion and new indications ahead](https://longbridge.com/en/news/298618645.md)
- [New FDA Drug Approvals - August 2026](https://longbridge.com/en/news/298751885.md)
- [Medicus selects 200 µg SkinJect patch as lead dose in final Phase 2 skin cancer study report](https://longbridge.com/en/news/298588900.md)
- [Castle Biosciences says JAAD study validates integrated DecisionDx-SCC test in high-risk skin cancer cohort of 572 patients](https://longbridge.com/en/news/298501409.md)
- [Intelligent Bio Solutions submits FDA 510(k) filing for fingerprint drug test system seeking codeine clearance](https://longbridge.com/en/news/298458663.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**